

Chordate's application for delisting has been approved

Chordate Medical Holding AB (publ) ("Chordate" or "the Company") application for delisting of the Company's ordinary shares with ISIN SE0022726139 and preference shares with ISIN SE0023848619 has now been approved by Nasdaq. The last day of trading on Nasdaq First North Growth Market is 4 March 2026.

For more information, please contact:

Member of the Swedish Bar Association Lars-Olof Svensson, liquidator
chordate@cms-wistrand.com
Phone: +46 8-507 200 00

About Chordate

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine, a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com

The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Bergs Securities AB.

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.

Attachments

[Chordate's application for delisting has been approved](#)